DY
DYN.US Dyne Therapeutics Inc
- Market cap
- USD 3.22B
- P/E
- -
- P/B
- 3.43x
- ROE
- -70.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DYN.US undervalued?
Graham numberThe Graham number of Dyne Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dyne Therapeutics Inc fundamental analysis
No fundamental analysis for Dyne Therapeutics Inc yet.
Dyne Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that del…
Full company profileDyne Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dyne Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.37B | 506M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -915M | -2.43B | -24.0K | -271K | -700K | -1.09M | -3.35M | -2.46M | -2.24M | -2.05M | - |
| Operating Income | -640M | -412M | -4.80M | -13.8M | -58.6M | -150M | -171M | -242M | -344M | -468M | -672M |
| EBITDA | 106M | 949M | -4.79M | -14.6M | -57.9M | -148M | -169M | -234M | -316M | -438M | -635M |
| Net Income | -1.24B | 76.0M | -4.81M | -13.5M | -58.7M | -149M | -165M | -236M | -317M | -446M | -657M |
| EPS | -9.61 | 0.47 | -0.47 | -0.30 | -1.24 | -2.93 | -3.18 | -3.95 | -3.37 | -3.47 | -3.62 |
| Balance Sheet | |||||||||||
| Total Assets | 13.1B | 11.8B | 8.27M | 16.4M | 353M | 426M | 306M | 165M | 691M | 1.19B | 1.23B |
| Total Liabilities | 11.0B | 9.87B | 13.1M | 2.40M | 11.0M | 57.5M | 54.0M | 73.8M | 61.4M | 215M | 304M |
| Shareholders' Equity | 2.04B | 1.90B | -4.88M | 14.0M | 342M | 368M | 252M | 91.3M | 630M | 972M | 931M |
| Cash & Short-term Investments | 1.91B | 397M | 8.12M | 14.6M | 345M | 377M | 256M | 123M | 642M | 1.11B | 1.13B |
| Total Debt | 8.98B | 8.43B | 3.38M | - | - | 32.6M | 30.5M | 27.4M | 24.0M | 20.3M | 244M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 676M | 585M | -4.16M | -11.8M | -46.5M | -120M | -154M | -188M | -292M | -403M | -604M |
| Capital Expenditure | 326M | 224M | 134K | 1.65M | 1.16M | 3.62M | 3.07M | 729K | 2.38M | 1.92M | 5.00M |
| Free Cash Flow | 350M | 361M | -4.30M | -13.5M | -47.7M | -123M | -157M | -189M | -295M | -405M | -609M |
| Ratios | |||||||||||
| ROE | -60.7% | 4.0% | - | -96.4% | -17.2% | -40.5% | -65.5% | -258.4% | -50.4% | -45.9% | -70.6% |
| ROA | -9.5% | 0.6% | -58.2% | -82.4% | -16.6% | -35.1% | -53.9% | -142.9% | -45.9% | -37.6% | -53.2% |
| Net Profit Margin | -90.8% | 15.0% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | 4.40x | 4.44x | - | - | - | 0.09x | 0.12x | 0.30x | 0.04x | 0.02x | 0.26x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dyne Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 22.0M | 0.14 | 28.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Dyne Therapeutics Inc
- Insiders 0.24%
- Institutions 99.76%
- Public & others 0.00%
- Shares outstanding 187M
- Free float 187M
Top funds holding DYN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock | 7.90M | 4.22% | +6.64% | Sep 2026 |
| Vanguard Health Care Inv | 6.11M | 3.26% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.27M | 2.81% | +0.34% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 4.76M | 2.54% | +3.22% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 4.67M | 2.49% | +2.69% | Oct 2026 |
| T. Rowe Price Instl Small-Cap Stock | 4.25M | 2.27% | +5.09% | Sep 2026 |
| T. Rowe Price Capital Appreciation | 3.99M | 2.13% | +7.89% | Sep 2026 |
| iShares Russell 2000 ETF | 3.91M | 2.09% | 0.00% | Oct 2026 |
| Fidelity Growth Company Fund | 3.16M | 1.68% | +1.21% | Aug 2026 |
| Janus Henderson Global Life Sciences D | 2.19M | 1.17% | 0.00% | Sep 2026 |
| Polar Capital Biotech S Inc | 2.16M | 1.15% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 2.13M | 1.14% | -0.56% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 2.11M | 1.12% | +2.01% | Aug 2026 |
| Fidelity Select Biotechnology | 2.06M | 1.10% | +0.63% | Aug 2026 |
| Vanguard Small Cap Index | 1.89M | 1.01% | -0.38% | Sep 2026 |
| Fidelity Small Cap Index | 1.66M | 0.89% | +0.16% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 1.39M | 0.74% | -9.87% | Jun 2026 |
| Worldwide Healthcare Ord | 1.28M | 0.68% | 0.00% | Jul 2026 |
| Orbis Optimal (US$) Fund | 1.27M | 0.68% | +41.55% | Mar 2026 |
| Vanguard MStar Small Cap Value Index | 1.23M | 0.66% | +1.96% | Sep 2026 |
Top institutions holding DYN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management,Inc. | 30.9M | 16.50% | +0.41% | Jun 2026 |
| BlackRock Inc | 12.4M | 6.62% | +6.02% | Jun 2026 |
| Jupiter Topco LLC | 12.0M | 6.40% | 0.00% | Jun 2026 |
| FMR Inc | 11.2M | 5.98% | +25.79% | Jun 2026 |
| State Street Corp | 7.46M | 3.98% | +12.09% | Jun 2026 |
| Orbis Allan Gray Ltd | 7.01M | 3.74% | +3.61% | Jun 2026 |
| Atlas Venture Life Science Advisors, LLC | 6.80M | 3.63% | -25.52% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.31M | 3.37% | -1.47% | Jun 2026 |
| TCG Crossover Management, LLC | 4.62M | 2.46% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.05M | 2.16% | -2.73% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 3.94M | 2.10% | +69.08% | Jun 2026 |
| FCPM III SERVICES BV | 3.85M | 2.05% | -17.14% | Jun 2026 |
| Geode Capital Management, LLC | 3.74M | 2.00% | +6.83% | Jun 2026 |
| Vestal Point Capital LP | 3.38M | 1.80% | -15.63% | Jun 2026 |
| Orbimed Advisors LLC | 3.24M | 1.73% | +10.89% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 3.15M | 1.68% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 3.15M | 1.68% | -3.13% | Jun 2026 |
| Armistice Capital, LLC | 3.09M | 1.65% | -2.77% | Jun 2026 |
| Perceptive Advisors LLC | 2.69M | 1.44% | -42.40% | Jun 2026 |
| Logos Global Management LP | 2.55M | 1.36% | +82.14% | Jun 2026 |
Dyne Therapeutics Inc company profile
- Company name
- Dyne Therapeutics Inc
- Ticker
- DYN.US
- Exchange
- USA Stocks
- Listed since
- Sep 17, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 322
- Fiscal year end
- December
- Address
- 1560 Trapelo Road, Waltham, MA, United States, 02451
- Phone
- 781 786 8230
- Website
- dyne-tx.com
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics Inc management
10- Mr. John G. Cox M.B.A.CEO, President & Director · born 1963
- Mr. Erick J. Lucera C.F.A., C.P.A.CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer · born 1968
- Dr. Oxana Beskrovnaya Ph.D.Chief Innovation Officer · born 1961
- Ms. Johanna Friedl-NadererChief Commercial Officer · born 1968
- Dr. Douglas Kerr M.B.A., M.D., Ph.D.Head of Research & Development and Chief Medical Officer · born 1967
- Dr. Axel WiestSenior VP and Head of Portfolio Strategy & Operations
- Dr. Rajesh Manchanda Ph.D.Chief Technical Officer · born 1967
- Mr. James P. Bilotta M.B.A.Chief Digital & Information Officer
- Mr. Alessandro MartuscelliChief Legal Officer
- Ms. Lucia CelonaChief Human Resource Officer · born 1966